XML 52 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Details) - Schedule of milulestone payments
 3 Months Ended
Mar. 31, 2021
USD ($)
Payment One [Member]  
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]  
Payment $ 50,000
Milestone Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product
Payment Two [Member]  
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]  
Payment $ 100,000
Milestone Dosing of first patient in a Phase 1 Clinical Trial of a Licensed Product
Payment Three [Member]  
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]  
Payment $ 250,000
Milestone Dosing of first patient in a Phase 2 Clinical Trial of a Licensed Product
Payment Four [Member]  
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]  
Payment $ 500,000
Milestone Receipt of New Drug Application ("NDA") (or foreign equivalent) approval for a Licensed Product
Payment Five [Member]  
Commitments and Contingencies (Details) - Schedule of milulestone payments [Line Items]  
Payment $ 1,000,000
Milestone Achievement of First Commercial Sale of Licensed Product